Trillium Announces Private Placement

TORONTO, ONTARIO -- (Marketwired) -- 11/15/17 -- Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has entered into subscription agreements for the sale of 1,950,000 common shares and 400,000 Series II non-voting convertible first preferred shares at a price of U.S.$8.50 per share, in a non-brokered private placement for gross proceeds of U.S.$19,975,000.Net proceeds from the private placement will be used to continue the development of TTI-621 in hematologic canc [...]


read full post from firmenpresse

(164893 Posts)

Leave a Reply